The urticaria drug market is dominated by oral medications, including steroids and second-generation, nondrowsy antihistamines, prescribed for both chronic inducible and chronic spontaneous urticaria. However, both drug classes have serious side effects, and many patients still struggle to control their lesions. As a result, the approval of Xolair has been welcomed by physicians and patients. Clinical trials for additional biological therapies are underway, capturing urticaria disease data using an array of clinical scoring systems. With only one biological drug currently approved, the most important factors for driving prescribing decisions remain unknown, and many of the unmet needs in this market remain unfulfilled.
Geographies: United States, EU5, Japan.
Primary research: 18 country-specific interviews with thought-leading allergists and dermatologists supported by survey data collected for this and other DRG research.
Epidemiology: Number of chronic urticaria patients by country, including diagnosed and drug-treated patients
Forecast: 10-year, annualized, drug-level sales and patient share of key chronic urticaria therapies through 2029, segmented by brands/generics.
Emerging therapies: Phase III / PR: 3 drugs; Phase II: 3 drugs; coverage of select preclinical and Phase I products
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.